HC Wainwright Analysts Boost Earnings Estimates for ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) – Equities researchers at HC Wainwright raised their Q2 2024 earnings per share estimates for ADMA Biologics in a report issued on Friday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $0.03 per share for the quarter, up from their prior estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is ($0.05) per share.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). ADMA Biologics had a negative return on equity of 13.54% and a negative net margin of 9.74%. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $62.13 million. During the same period in the previous year, the business earned ($0.08) earnings per share. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year.

Other analysts also recently issued reports about the company. Cantor Fitzgerald lifted their price target on ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Mizuho lifted their price target on ADMA Biologics from $6.00 to $7.00 in a research note on Thursday, August 10th. StockNews.com upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Raymond James boosted their target price on ADMA Biologics from $5.00 to $6.00 and gave the stock a “strong-buy” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $6.00.

ADMA Biologics Stock Down 1.6 %

ADMA Biologics stock opened at $3.77 on Monday. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.35 and a quick ratio of 2.49. ADMA Biologics has a 1-year low of $2.94 and a 1-year high of $4.65. The company has a market cap of $847.91 million, a PE ratio of -34.27 and a beta of 0.79. The stock’s 50 day moving average price is $3.52 and its 200 day moving average price is $3.76.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently made changes to their positions in ADMA. Tucker Asset Management LLC acquired a new position in shares of ADMA Biologics in the first quarter worth $31,000. Virtu Financial LLC acquired a new position in shares of ADMA Biologics in the second quarter worth $34,000. Envestnet Asset Management Inc. acquired a new position in shares of ADMA Biologics in the first quarter worth $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of ADMA Biologics in the second quarter worth $35,000. Finally, Stephens Consulting LLC acquired a new position in shares of ADMA Biologics in the third quarter worth $36,000. 73.58% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jerrold B. Grossman bought 130,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average cost of $3.71 per share, for a total transaction of $482,300.00. Following the completion of the transaction, the director now owns 443,265 shares in the company, valued at $1,644,513.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Brian Lenz sold 211,578 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $4.60, for a total value of $973,258.80. Following the completion of the transaction, the chief financial officer now directly owns 782,013 shares of the company’s stock, valued at $3,597,259.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman purchased 130,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was bought at an average cost of $3.71 per share, with a total value of $482,300.00. Following the completion of the acquisition, the director now owns 443,265 shares of the company’s stock, valued at $1,644,513.15. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 2,405,351 shares of company stock worth $9,875,175. 6.00% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.